collaboration-kings-college-london
Boehringer Ingelheim and the IoPPN at King’s College London partner to progress new therapeutic concepts in major depressive disorder and schizophrenia
Search
10 things you should know about rabies
10 things you should know about rabies
Full data chronic kidney disease trial efficacy
Positive full data results announced from the EMPA-KIDNEY Phase III trial in adults with chronic kidney disease
cat dog flea allergy dermatitis
Find out how you can identify and treat flea allergy dermatitis, one of the most common illnesses associated with a flea infestation.
Spesolimab meets key endpoint for GPP flare prevention
Spesolimab meets primary and key secondary endpoint for prevention of generalized pustular psoriasis flares
2019 performance
Global Support Program addresses COVID-19 crisis with relief fund initiatives and volunteering support, donations, and concrete research activities.
Boehringer Ingelheim good 2021 business performance
2021 was a good year for patients, for animal owners and for Boehringer Ingelheim.
2020-Positive-business-momentum-despite-COVID-19-impact
While stepping up its investments in R&D significantly, Boehringer Ingelheim achieved a solid business performance in 2020 despite the COVID-19 pandemic.
CHMP_opinion_nintedanib_ILD_PF
Nintedanib received a CHMP positive opinion for the treatment of patients with other chronic fibrosing ILDs with a progressive phenotype beyond IPF
The little things
In 2009 Anna was diagnosed with scleroderma. For her, however, the disease is no reason to give up. On the contrary.
Leticia develops product medical strategies
Leticia develops product medical strategies at Boehringer Ingelheim. For more talent insights, visit our Careers Page.
Mareks Disease Poultry Chicken
Five things you need to know to keep poultry free from outcomes of one of the most common virus affecting the animals’ immune systems.
EC_approval_nintedanib_ILD_PF
European Commission approves nintedanib for the treatment of patients with other chronic fibrosing ILDs with a progressive phenotype beyond IPF
S&P Animal Health Partnering Oct 2023
Interview by S&P Global with Megan Grether, discussing Boehringer Ingelheim Animal Health Partnering’s ambition and approach
Careers beyond borders
Careers beyond borders
Microbial Expertise
Microbial systems are ideal for synthesizing smaller and non-glycosylated proteins. Due to the variety of molecular formats that can be synthesised by microbes, microbial manufacturing is characterized by a broad width of production processes.
Interstitial lung disease in rheumatoid arthritis (RA-ILD)
Interstitial lung disease (ILD) is the most common type of lung condition associated with the systemic autoimmune disease rheumatoid arthritis (RA).
Combating food insecurity for more health equity in the U.S.
Meet social innovation founder Katie at Making More Health Together 2023: How the social innovation founder brings fresh food stores back to the U.S.
Breakthrough in Artificial Intelligence ChatGPT
Is ChatGPT the AI revolution we were waiting for or only media hype? Experts from Boehringer Ingelheim take a close look.
Ofev®
Ofev® is a prescription medication used to treat people with idiopathic pulmonary fibrosis (IPF) systemic sclerosis-associated interstitial lung disease (SSc-ILD) and other chronic fibrosing interstitial lung diseases with a progressive phenotype
ArisGlobal acquires Boehringer Ingelheim technology
Boehringer Ingelheim’s signal analytics technology is acquired by ArisGlobal
Top Employer: learning and development with an impact
David has been part of us for over 20 years. What has kept him is part of what makes us a Global Top Employer 2024: our learning and development offerings.
Metabolic Diseases
Metabolic Diseases
Use of data: "A game changer for our industry"
Data is a game changer for the pharmaceutical industry and will shape our business. Listen to our podcast.
opening-solids-launch-fabrik
Boehringer Ingelheim today opened a tablet factory at Ingelheim in the presence of the State Premier of Rhineland-Palatinate, Malu Dreyer.